Drug Profile


Alternative Names: HBAI 20 - CyTuVax; HBAI-20

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CyTuVax
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 21 Sep 2017 Phase-II clinical trials in Hepatitis B prevention (Prevention) in Netherlands (IM) (EudraCT2016-002720-91)
  • 19 Apr 2017 Additional immunogenicity and adverse events data from a phase I trial in Hepatitis B prevention presented at the International Liver Congress 2017 (ILC-2017)
  • 29 Apr 2016 Interim immunogenicity and adverse events data from a phase I trial in Hepatitis B prevention released by CyTuVax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top